#UPB

2 weeks ago

Upstream Bio Presents Additional Analyses from the Phase 2 VIBRANT Trial of Verekitug in Chronic Rhinosinusitis with Nasal Polyps at 2026 AAAAI Annual Meeting Upstream Bio (Nasdaq:UPB) presented additional Phase 2 VIBRANT data for verekitug in chronic rhinosinusitis with nasal polyps (CRSwNP) at the AAAAI 2026 meeting. WOCF-adjusted analyses showed a placebo-adjusted NPS reduction of -1.95 (p < 0.0001) and NCS reduction of -0.96 (p < 0.0001) at Week 24.The trial (n=81) also reported a 76% reduction in need for surgery or systemic corticosteroids (p=0.03), an acceptable safety profile with no SAEs observed, and plans to initiate Phase 3 registrational trials in CRSwNP and severe asthma.

#UPB Upstream Bio Presents Additional Analyses from the Phase 2 VIBRANT Trial of Verekitug in Chronic Rhinosinusitis with Nasal Polyps at 2026 AAAAI Annual Meeting

www.stocktitan.net/news/UPB/upstream-bio-pr...

0 0 0 0

Belgienzentrum der Universität Paderborn

@belzpb.bsky.social

1 month ago

🇧🇪✨ Save the Date: 10. Belgientag
Merkt euch den 10. Juni 2026 im Kalender vor! 🎉 Das Programm teilen wir bald auf unseren Socials – folgt uns also gerne, damit ihr nichts verpasst!

#BelgienTag #SaveTheDate #upb #ComingSoon #BELZ

0 1 0 0

StockTitan

@stocktitan.net

4 months ago

Upstream Bio Reports Third Quarter 2025 Financial Results and Highlights Continued Progress Upstream Bio (Nasdaq: UPB) reported Q3 2025 results and program progress for verekitug, a TSLP receptor antagonist targeting severe respiratory diseases.Key clinical highlights: VIBRANT Phase 2 in CRSwNP met its primary endpoint with a placebo-adjusted endoscopic NPS reduction of -1.8 (p<0.0001), nasal congestion improvement -0.8 (p=0.0003), and a 76% reduction in need for surgery or systemic corticosteroids (p=0.03). VALIANT Phase 2 top-line data in severe asthma are expected in Q1 2026; VENTURE COPD trial enrollment is ongoing after first patient dosed in July 2025.Financials: cash, equivalents and short-term investments of $372.4M expected to fund operations through 2027; Q3 R&D expense $33.0M; Q3 net loss $33.7M.

#UPB Upstream Bio Reports Third Quarter 2025 Financial Results and Highlights Continued Progress

www.stocktitan.net/news/UPB/upstream-bio-re...

0 0 0 0

México Se Entere

@mexe.mx

4 months ago

MARA LEZAMA IMPULSA EDUCACIÓN DOCENTE

La gobernadora Mara Lezama firma convenios con #UPB y #UPQROO para fortalecer la capacitación docente en #QuintanaRoo.

🔗Detalles aquí👉 https://f.mtr.cool/omojfiuyif

0 0 0 0

@rolbis.bsky.social

5 months ago

The Pontifical Bolivarian University and 2030 Agenda: Scientific Production, Access Modalities, and Social Media Impact – Journal of Scientometric Research

Journal of Scientometric Research. Artículo analiza la producción científica de la UPB y su vínculo con la Agenda 2030. Hallamos que el acceso abierto se asocia con mayor visibilidad y que persisten retos en ODS clave
DOI: doi.org/10.5530/jsci...
#CienciaAbierta #OpenAccess #ODS #Scientometrics #UPB

0 0 0 0

Belgienzentrum der Universität Paderborn

@belzpb.bsky.social

6 months ago

A1 Kurse finden im kommenden WiSe mittwochs statt - wahlweise ab 9:30 oder ab 11:00. Schaut für alle weiteren Kurse gerne auf der Seite des @zfs.upb vorbei!

#Niederländisch #LearnDutch #Nederlandsleren #Fremdsprachen #UPB #Benelux #Belgien #Reisen

0 0 0 0

StockTitan

@stocktitan.net

6 months ago

76% Less Surgery Need: Upstream Bio's Nasal Polyp Drug Verekitug Shows Breakthrough Phase 2 Results Phase 2 VIBRANT trial met primary endpoint with -1.8 NPS reduction. Verekitug showed -0.8 nasal congestion improvement and 76% reduced surgery need. No serious adverse events reported.

#UPB Upstream Bio Reports Positive Top-Line Results from the Phase 2 VIBRANT Trial of Verekitug for the Treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

www.stocktitan.net/news/UPB/upstream-bio-re...

0 0 0 0

Kengar Dongatron

@kengar-m-dongatron.bsky.social

6 months ago

THE KOCKTER KOPTER KILL IS CRAZY INSANE! SO TODAY IM GONNA STREAM A #SMASH OPEN ARENA! JOIN ME ON MY #TWITCH at ttv/kengar_m_dongatron 7pm est #krool #smash #bowser #upb

0 0 0 0

Nasdaq

@nasdaq.activitypub.awakari.com.ap.brid.gy

7 months ago

Upstream Bio (UPB) Q2 R&D Soars 169% | The Motley Fool

#UPB #5f5b9c5a-98ec-4135-944e-68ddc542bb0a #data-news

Origin | Interest | Match

0 0 0 0

StockTitan

@stocktitan.net

7 months ago

Upstream Bio Reports Second Quarter 2025 Financial Results and Highlights Continued Progress Upstream Bio (NASDAQ:UPB) reported Q2 2025 financial results and clinical progress for its lead drug verekitug, the only monoclonal antibody targeting TSLP receptor in development. The company highlighted three key clinical trials: VIBRANT (CRSwNP) with top-line data expected in Q3 2025, VALIANT (severe asthma) with results in Q1 2026, and VENTURE (COPD) which dosed its first patient in July 2025.Financially, Upstream reported cash position of $393.6 million, expected to fund operations through 2027. Q2 2025 showed a net loss of $40.0 million, up from $14.7 million in Q2 2024, primarily due to increased R&D expenses of $37.9 million and G&A expenses of $7.4 million. [ "Strong cash position of $393.6 million, funding operations through 2027", "Completed enrollment in Phase 2 severe asthma trial ahead of Q1 2026 data readout", "On track for CRSwNP Phase 2 trial results in Q3 2025", "Expanded clinical program with first COPD patient dosed in July 2025" ]

#UPB Upstream Bio Reports Second Quarter 2025 Financial Results and Highlights Continued Progress

www.stocktitan.net/news/UPB/upstream-bio-re...

0 0 0 0

StockTitan

@stocktitan.net

8 months ago

Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease (COPD) Upstream Bio (NASDAQ:UPB) has initiated dosing in its Phase 2 clinical trial, VENTURE, evaluating verekitug for Chronic Obstructive Pulmonary Disease (COPD). The trial will assess approximately 670 adults with moderate-to-severe COPD, testing doses of 100 mg every 12 weeks or 400 mg every 24 weeks versus placebo.This expansion marks verekitug's third indication in development, alongside ongoing Phase 2 trials in chronic rhinosinusitis with nasal polyps (CRSwNP) and severe asthma. The company has completed enrollment for both existing trials, with data expected in Q3 2025 for CRSwNP and Q1 2026 for severe asthma.Verekitug, as the only known biologic targeting the TSLP receptor, aims to improve COPD treatment through less frequent dosing and potentially differentiated efficacy compared to existing biologics.

#UPB Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease (COPD)

www.stocktitan.net/news/UPB/upstream-bio-an...

0 0 0 0

StockTitan

@stocktitan.net

9 months ago

Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor Upstream Bio (UPB) presented translational pharmacology modeling data for verekitug, their novel antibody antagonist targeting the TSLP receptor, at the EAACI Congress. The data demonstrates verekitug's greater potency compared to tezepelumab in treating inflammatory diseases. The modeling shows complete and sustained inhibition of the TSLP/TSLPR complex and predicts greater reduction in FeNO, a lung inflammation biomarker. This superior efficacy is attributed to lower TSLP receptor expression levels and slower protein turnover compared to the ligand. Verekitug is currently in Phase 2 trials for severe asthma, COPD, and CRSwNP, with topline data expected in Q3 2025 for CRSwNP and H1 2026 for severe asthma.

#UPB Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor

www.stocktitan.net/news/UPB/translational-d...

0 0 0 0

ETS de Ingeniería y Diseño Industrial. UPM

@etsidi-upm.bsky.social

10 months ago

La #ETSIDI participa en el evento #steampact en la Universidad Politécnica de Bucarest .
Una actividad organizada por @eelisa_eu
Trabajamos alumnado, profesorado y personal de investigación en unión a favor de los #ODS
#InnovateTogether #SDGs #STEAM #UPB
#Sociallmpact

0 0 0 0

StockTitan

@stocktitan.net

10 months ago

Upstream Bio Reports First Quarter 2025 Financial Results and Accelerates Guidance on All Clinical Programs Upstream Bio (NASDAQ: UPB) reported its Q1 2025 financial results and accelerated guidance for its clinical programs. The company is developing verekitug, the only monoclonal antibody targeting the TSLP receptor in clinical development. Key updates include: top-line data from Phase 2 trial in chronic rhinosinusitis with nasal polyps expected in Q3 2025, Phase 2 data for severe asthma now anticipated in H1 2026, and first patient dosing in COPD trial expected mid-2025. Financially, Upstream reported cash position of $431.4M expected to fund operations through 2027. Q1 2025 showed R&D expenses of $25.8M (up from $11.7M in Q1 2024) and a net loss of $27.3M (compared to $10.9M in Q1 2024). The company completed enrollment for its CRSwNP Phase 2 trial in January 2025, with patients receiving 100mg verekitug or placebo every 12 weeks over 24 weeks.

#UPB Upstream Bio Reports First Quarter 2025 Financial Results and Accelerates Guidance on All Clinical Programs

www.stocktitan.net/news/UPB/upstream-bio-re...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

10 months ago

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with improving money flow, Thu Apr 17th - #UPB #SHFS #AOBI #AGEN #CMRX #DXPE #IMG #JANX #KOD #TATT #PFBC #NEXN #WBX #SBH #RMT #ORN #LEO #FBMS - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

Asa Cauvel

@fresh-af-fungi.bsky.social

11 months ago

Just saw Robin Wall Kimmerer at UPB over at Bromeley Theater. My wife and I had an awesome time. I definitely recommend her books, she's got a lot of important things to say esp about ecology and botany etc. ...

I really appreciate the University of Pittsburgh at Bradford for having her. #UPB

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Upstream Bio Secures 3-Year Runway with $470M War Chest, Advances 3 Clinical Programs Upstream Bio strengthens position with $293M IPO and robust pipeline progress. Cash runway extended through 2027, advancing verekitug across three respiratory disease programs.

#UPB Upstream Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

www.stocktitan.net/news/UPB/upstream-bio-re...

0 0 0 0

ENFIELD - AI Network of Excellence

@horizonenfield.bsky.social

1 year ago

🌟Day 2 of ENFIELD’s 3rd General Assembly in #Budapest🌟

✅ Tasks 2.1-2.4 by #SINTEF, #IMT, #TUE, #NTNU
✅ Tasks 3.1-3.4 by #POLIMI, #ICCS, #ECoE
✅ Tasks 4.1-4.4 by #IMT, #TALTECH, #UPB, #DTI
✅ Closed with reflections by #NTNU & #BME
Onward to more innovation!
#ENFIELD_Horizon